Back
M
Mingwei Chen
southern university of science and technology
122H-index
647Paper Count
7.0WCitation Count
Published Papers 363
Publication Date
Phase II study of pembrolizumab (pemb) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after failure on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on Immune Re-sensitization
ANNALS OF ONCOLOGY
IF65.4

